




Expansion of Out-Patient Parenteral Antimicrobial Therapy (OPAT) service provision for patients using alternative drug delivery devices

Marie Woodley IV / OPAT manager / Dr Ruby Devi Consultant Microbiologist
 Team members: Elizabeth Peacock, Grant Sear, Maryann Imperial.
 Antimicrobial Pharmacists: Claire Brandish, Aarash Ahmadi
 Contact details: 01296 315485 bht.opat@nhs.net

Aim: To improve patients experience and increase our service provision by offering further opportunities to be treated at home or in an outpatient setting with alternative drug delivery devices, while not compromising on the best available choice of treatment

Project background / Introduction
 The OPAT service was established in 2010 to facilitate early supported discharge or admission avoidance to allow patients home who need supportive care with antimicrobial therapy and reduce the need to stay in hospital for the duration of the IV antibiotic(s).
 Since the OPAT service was established, it has explored innovative ways of how antimicrobials can be used safely and effectively to facilitate these models of care, in the comfort and safety of patients' own homes.
 The OPAT service vision was to expand self-administration by patients / carers as much as possible. The use of pre-filled elastomeric device was explored as a key element of this expansion. It was trialled using the introduction of the pre-filled 30-minute once-a-day treatments, with positive outcomes from patient experience surveys, including self-administration and reduced visit times per patient for the community teams.
 The OPAT service has since implemented fully functional pathways for a variety of 30-minute and 24-hour pre-filled elastomeric device(s) supplied from Baxter.



Stakeholder Engagement
 Patients, anti-infective pharmacists, Microbiology consultants, Pharmacy procurement, community nursing teams, Baxter

Conclusion & next steps:

- The outcome of expansion of the service with the elastomeric devices has been positive. We will continue with expanding the remit of treatments and patient choice the OPAT service can provide.
- Scoping for further opportunities to provide an increased range of IV (and oral) treatments available as a homebased/ outpatient treatment.
- Continue to collect patient outcome and experience data to drive improvements.

Quality, Efficiency and/or Financial Benefits: Alongside bed days and cost savings from our other treatment pathways, the introduction of the elastomeric device(s) has enabled OPAT to treat an additional 106 patients, saved 1764 bed days and realised a cost saving of £414,669 over 3 years. The reduction in hospital stay solely for IV antibiotic therapy is a proven method of improving patients' experience.